A vaccine is being our vaccine. Our oral color vaccine is given to companies to, make without any benefit i. B. I. , our goal is to Impact Global health. And, and if we can do that in any way possible, then weve accomplished our mission. Well, you mention the Gates Foundation, their Research Suggests that global cova debts will double of high Income Countries by up to the 1st 2000000 doses of any successful vaccine. Do you agree with so thats a great study and weve been using it to advocate for something called codex. The kovacs cicelys is an organization under the leadership of the World Health Organization set, b. And gabby 192. 00 countries signed on to get 2000000000 doses of vaccine w. H. O. Approved vaccine by the end of 2021. And it will be given to the countries that are part of the facility, not how can 192 of them roughly 20 percent of their needs for now. And thats actually really important because its never been the case before that innovative Vaccine Technology has made it
Approved exene by the end of 2021, and it will be given to the countries that are part of the facility, not how can 192 of them roughly 20 percent of their needs for now. And thats actually really important because its never been the case before that innovative Vaccine Technology has made its way from the laboratory, through the clinic, through a big Multinational Corporation or a Chinese Company or an indian company. And then out into Global Health it at roughly the same time that its available in the United States, u. K. And europe. So in a sense, kovacs is a victory for those people who believe in multilateralism in transparency, you know, unfortunately there are 2 big standouts from kovacs. Its the United States and this and russia. Unfortunately, they should join. Well, its interesting that neither of those 2 countries do, and both of those countries obviously have those vaccines. But if you know nothing about vaccines, not as much as you do and youre sitting here watching this, a
Companies have the same time. You see that the richest countries in the world, the buying hundreds of millions of doses of these vaccines, specially in the context of that gates research. I dont have any worry that what youre doing isnt going to be enough to stop all the successful vaccines being taken by the rich of us as the poor. So i think that thats a very interesting analysis. And if you look at the total number of doses that the high income countries, but also india and brazil have purchased, its about 8800000000 doses are in excess of what they need. So what you, when you really look at it, there are a number of contracts and there are preorders contingent orders. So how that will play out in the end . Were not sure. But the more important point i think here is that kodaks intends to purchase 2000000000. 00 doses, and those doses will be provided to everyone and what cannot paper the Gates Foundation paper you quoted says, is that if the 1st 2000000. 00 doses are taken without
Have our own back seen. It makes kind of companies uncomfortable when we tell them its. Were working on our own vaccine to see what wed decided was to support companies which every company came to us for assistance, helping them with assays with Animal Studies with clinical trials, with regulatory pathways. Anything that we needed to do in order to advance a vaccine as quickly as possible. So in a sense, if the world wins that i. B. I. Wins, and that was our strategy, that being advocates of free market, Big Pharmaceutical Companies will say, and your, or your a strategy failed it is pfizer astra zeneca, those big multinationals that create the vaccines no, into your a un mandated vaccine institute. So actually, you know, our Vaccines Institute is, is funded really by, you know, the governments of korea, sweden, india, and finland and the Gates Foundation. The Welcome Trust. And our goal is really to get vaccines over the finish line. I mean, we dont think about it that vaccine is bein
Sunday, october 4th, a at noon eastern on book tv on cspan2. And now, Georgetown University law center previews the Upcoming Supreme Court term including one case challenging the constitutionality of the Affordable Care act. They also talk about the potential for lawsuits concerning the 2020 elections that may reach the Supreme Court for consideration and reflects on the passing of Ruth Bader Ginsburg and her legacy in the court and the legal profession. This is about two hours. Welcome, everyone, to our annual Supreme Court term preview. Im executive director of the Supreme Court institute at georgetown law. Before we get started with todays scheduled program, i want to take the opportunity to acknowledge the passing of Justice Ginsburg. She was a trail blazing civil rights lawyer, a giant of a juress and a larger than life human being. But what i will remember most about her is her indom spirit. That and the devastate iing ser of questions she hurled my way at oral argument in the wi